Shannon K
Department of Pediatrics, University of California, School of Medicine, San Francisco, USA.
Clin Perinatol. 1995 Sep;22(3):627-40.
Recombinant human erythropoietin (r-HuEPO) is a new therapeutic modality for the treatment of neonatal anemia. The results of three large controlled trials were published within the past year. This article reviews the physiologic rationale underlying the use of r-HuEPO in preterm infants, addresses how the design of clinical trials affects outcomes and conclusions, and discusses the recent trials in this context. The article concludes with a summary of questions that require further investigation.
重组人促红细胞生成素（r-HuEPO）是治疗新生儿贫血的一种新的治疗方式。过去一年里发表了三项大型对照试验的结果。本文回顾了在早产儿中使用r-HuEPO的生理依据，探讨了临床试验的设计如何影响结果和结论，并在此背景下讨论了最近的试验。文章最后总结了需要进一步研究的问题。
